Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Z Li

Showing results (111-120 of 270) with videos related to

Pageof 27
Sort By:
Medrxiv : the Preprint Server for Health Sciences|September 10, 2020
Rapid 'mix and read' assay for scalable detection of SARS-CoV-2 antibodies in patient plasmaHong Yue, Radosław P Nowak, Daan Overwijn, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 3, 2018
Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized TrialBabafemi O Taiwo, Vincent C Marconi, Baiba Berzins, et al.
Annals of Internal Medicine|February 21, 2023
Symptom and Viral Rebound in Untreated SARS-CoV-2 InfectionRinki Deo, Manish C Choudhary, Carlee Moser, et al.
The Journal of Infectious Diseases|October 13, 2010
Xenotropic murine leukemia virus-related virus prevalence in patients with chronic fatigue syndrome or chronic immunomodulatory conditionsTimothy J Henrich, Jonathan Z Li, Donna Felsenstein, et al.
Contemporary Clinical Trials|March 27, 2025
Implementation of a seamless phase 2/3 study design in the setting of an emergent infectious disease pandemic: Lessons learned from the ACTIV-2 platform COVID-19 treatment trialMark J Giganti, Kara W Chew, Carlee Moser, et al.
Medrxiv : the Preprint Server for Health Sciences|August 19, 2022
Viral and Symptom Rebound in Untreated COVID-19 InfectionRinki Deo, Manish C Choudhary, Carlee Moser, et al.
The Journal of Infectious Diseases|December 25, 2012
Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failureJonathan Z Li, Roger Paredes, Heather J Ribaudo, et al.
Pathogens & Immunity|March 20, 2024
Erratum to: Progress Note 2024: Curing HIV; Not in My Lifetime or Just Around the Corner?Justin Harper, Michael R Betts, Mathias Lichterfeld, et al.
The Journal of Infectious Diseases|December 11, 2024
Viral and Immune Risk Factors of HIV Rebound After Interruption of Antiretroviral TherapyS Gianella, T Yu, R Wang, et al.
AIDS (London, England)|June 5, 2014
Prevention of HIV-1 transmission with postexposure prophylaxis after inadvertent infected blood transfusionSami H Al-Hajjar, Husn H Frayha, Mohammad Al-Hazmi, et al.
Pageof 27

Showing results (111-120 of 270) with videos related to

Sort By:
Pageof 27
Medrxiv : the Preprint Server for Health Sciences|September 10, 2020
Rapid 'mix and read' assay for scalable detection of SARS-CoV-2 antibodies in patient plasmaHong Yue, Radosław P Nowak, Daan Overwijn, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 3, 2018
Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized TrialBabafemi O Taiwo, Vincent C Marconi, Baiba Berzins, et al.
Annals of Internal Medicine|February 21, 2023
Symptom and Viral Rebound in Untreated SARS-CoV-2 InfectionRinki Deo, Manish C Choudhary, Carlee Moser, et al.
The Journal of Infectious Diseases|October 13, 2010
Xenotropic murine leukemia virus-related virus prevalence in patients with chronic fatigue syndrome or chronic immunomodulatory conditionsTimothy J Henrich, Jonathan Z Li, Donna Felsenstein, et al.
Contemporary Clinical Trials|March 27, 2025
Implementation of a seamless phase 2/3 study design in the setting of an emergent infectious disease pandemic: Lessons learned from the ACTIV-2 platform COVID-19 treatment trialMark J Giganti, Kara W Chew, Carlee Moser, et al.
Medrxiv : the Preprint Server for Health Sciences|August 19, 2022
Viral and Symptom Rebound in Untreated COVID-19 InfectionRinki Deo, Manish C Choudhary, Carlee Moser, et al.
The Journal of Infectious Diseases|December 25, 2012
Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failureJonathan Z Li, Roger Paredes, Heather J Ribaudo, et al.
Pathogens & Immunity|March 20, 2024
Erratum to: Progress Note 2024: Curing HIV; Not in My Lifetime or Just Around the Corner?Justin Harper, Michael R Betts, Mathias Lichterfeld, et al.
The Journal of Infectious Diseases|December 11, 2024
Viral and Immune Risk Factors of HIV Rebound After Interruption of Antiretroviral TherapyS Gianella, T Yu, R Wang, et al.
AIDS (London, England)|June 5, 2014
Prevention of HIV-1 transmission with postexposure prophylaxis after inadvertent infected blood transfusionSami H Al-Hajjar, Husn H Frayha, Mohammad Al-Hazmi, et al.
Pageof 27